Enveric Biosciences, Inc.

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

ENVB$1.44+1.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Shareholders’ Equity

Common Stock · Additional Paid-In · Accumulated · Accumulated Other Comprehensive · Total Shareholders’
Shares · Amount · Capital · Deficit · Loss · Equity
Balance at January 1, 2025	56,501	$565	$108,261,264	-	$(106,074,505)	$(594,517)	$1,592,807
Issuance of Common Stock and Series A and B and prefunded warrants for cash, net of offering costs of $755,487	102,444	1,024	4,243,443		—	—	4,244,467
Issuance of common shares for vested RSAs	39,380	393	(393)		—	—	—
Issuance of common shares for exercise of warrants	38,528	385	74,659		—	—	75,044
Issuance of round up shares	85,965	860	(860)		—	—	—
Issuance of common shares for cash pursuant to ATM Agreement, net of offering costs of $217,079	110,242	1,103	1,635,696		—	—	1,636,799
Exercise of Series A, B, C, and D Warrants for common shares, net of offering costs of $988,911	628,473	6,285	4,552,324		—	—	4,558,609
Deemed dividend on inducement of warrants of $3,359,485	—	—	—		—	—	—
Stock-based compensation	—	—	827,323		—	—	827,323
Foreign exchange translation gain	—	—	—		—	14,479	14,479
Net loss	—	—	—	-	(8,771,987)	—	(8,771,987)
Balance at December 31, 2025	1,061,533	$10,615	$119,593,456	-	$(114,846,492)	$(580,038)	$4,177,541

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

Common Stock · Additional Paid-In · Subscription · Accumulated · Accumulated Other Comprehensive · Total Shareholders’
	Shares	Amount	Capital	Receivable	Deficit	Loss	Equity
Balance at January 1, 2024	15,219	$152	$100,843,091	$(1,817,640)	$(96,499,518)	$(569,749)	$1,956,336
Common stock sold under the Equity Distribution Agreement, net of offering costs of $583,713	9,267	93	1,808,696	—	—	—	1,808,789
Issuance of direct offering shares (see Note 7)	3,816	38	771,255	—	—	—	771,293
Exercise of Inducement Warrants for common stock	10,856	109	2,676,871	—	—	—	2,676,980
Stock based compensation	—	—	1,562,392	—	—	—	1,562,392
Issuance of common shares for vested RSU	153	1	(1)	—	—	—	—
Proceeds from the subscription receivable related to the issuance of Inducement Warrants, net of offering costs of $12,821	—	—	(12,821)	280,500	—	—	267,679
Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance	3,912	39	(39)	1,537,140	—	—	1,537,140
Common stock sold under the Purchase Agreement, net of offering costs of $471,756	13,278	133	611,820	—	—	—	611,953
Foreign exchange translation loss	—	—	—	—	—	(24,768)	(24,768)
Net loss	—	—	—		(9,574,987)	—	(9,574,987)
Balance at December 31, 2024	56,501	$565	$108,261,264	$—	$(106,074,505)	$(594,517)	$1,592,807

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.